1. What is the projected Compound Annual Growth Rate (CAGR) of the Infectious Disease Point-of-care (POC) Diagnostics Market?
The projected CAGR is approximately 6.5%.
+1 2315155523
MR Forecast provides premium market intelligence on deep technologies that can cause a high level of disruption in the market within the next few years. When it comes to doing market viability analyses for technologies at very early phases of development, MR Forecast is second to none. What sets us apart is our set of market estimates based on secondary research data, which in turn gets validated through primary research by key companies in the target market and other stakeholders. It only covers technologies pertaining to Healthcare, IT, big data analysis, block chain technology, Artificial Intelligence (AI), Machine Learning (ML), Internet of Things (IoT), Energy & Power, Automobile, Agriculture, Electronics, Chemical & Materials, Machinery & Equipment's, Consumer Goods, and many others at MR Forecast. Market: The market section introduces the industry to readers, including an overview, business dynamics, competitive benchmarking, and firms' profiles. This enables readers to make decisions on market entry, expansion, and exit in certain nations, regions, or worldwide. Application: We give painstaking attention to the study of every product and technology, along with its use case and user categories, under our research solutions. From here on, the process delivers accurate market estimates and forecasts apart from the best and most meaningful insights.
Products generically come under this phrase and may imply any number of goods, components, materials, technology, or any combination thereof. Any business that wants to push an innovative agenda needs data on product definitions, pricing analysis, benchmarking and roadmaps on technology, demand analysis, and patents. Our research papers contain all that and much more in a depth that makes them incredibly actionable. Products broadly encompass a wide range of goods, components, materials, technologies, or any combination thereof. For businesses aiming to advance an innovative agenda, access to comprehensive data on product definitions, pricing analysis, benchmarking, technological roadmaps, demand analysis, and patents is essential. Our research papers provide in-depth insights into these areas and more, equipping organizations with actionable information that can drive strategic decision-making and enhance competitive positioning in the market.
Infectious Disease Point-of-care (POC) Diagnostics MarketInfectious Disease Point-of-care (POC) Diagnostics Market by Technique (Lateral Flow Immunoassay, Agglutination Test, Others), by Disease (HIV, Hepatitis B Virus, Pneumonia/Streptococcus Associated Infections, RSV, Influenza, Clostridium Difficile Infections, Hepatitis C Virus, Methicillin-Resistant Staphylococcus Aureus, Tuberculosis, Others), by Disease, COVID-19 Point-of-care (POC), by End User (Hospital Bedside, Physicians Office Lab, Urgent Care & Retail Clinics, Others), by By Geography (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) Forecast 2026-2034
The Infectious Disease Point-of-care (POC) Diagnostics Market size was valued at USD 15.81 USD Billion in 2023 and is projected to reach USD 24.57 USD Billion by 2032, exhibiting a CAGR of 6.5 % during the forecast period. Infectious Disease POC (Point-of-care) Diagnostics is an approach to test exhilaration rapidly and precisely that can be performed anywhere at the site of an infection. They vary depending on their target, application, and assay type including nucleic acid amplification tests (NAATs), immunoassays, and molecular assays. As NAATs detect the genetic material of pathogens, immunoassays define the presence of different types of antibodies or antigens by the immune system. DNA and RNA detection is based on the molecular method of PCR, which includes amplification and discovery. POC diagnostics provide benefits such as easy access, transportability, and fast results placing them among the few most useful diagnostic tools in resource-limited counties, emergency departments, and the remotest of areas. They enable early diagnosis, health monitoring, and outbreak control procedures as well as ensure patient care without the need of lab facilities which are often lack in certain places.
-Diagnostics-Market.png&w=1920&q=75)
-Diagnostics-Market.png&w=1920&q=75)
By Technique:
By Disease:
By COVID-19 Point-of-care:
By End User:
Our updated report provides a comprehensive and in-depth analysis of the global Infectious Disease Point-of-care (POC) Diagnostics Market, delivering:
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 6.5% from 2020-2034 |
| Segmentation |
|
Note*: In applicable scenarios
Primary Research
Secondary Research
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
The projected CAGR is approximately 6.5%.
Key companies in the market include F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Abbott Laboratories (U.S.), Quest Diagnostics Incorporated (U.S.), BD (U.S.), bioMérieux SA (France), Cardinal Health, Inc. (U.S.), Cepheid (U.S.), Trinity Biotech (Ireland), Quidel Corporation (U.S.), Bio-Rad Laboratories Inc. (U.S).
The market segments include Technique, Disease, Disease, COVID-19 Point-of-care, End User.
The market size is estimated to be USD 15.81 USD Billion as of 2022.
Introduction of Cost-effective Manufacturing Processes to Drive Market Growth.
Increasing Number of Hospitals and ASCs Identified as Significant Market Trend.
Lack of Accuracy Associated with Point-of-care Diagnostics Tests to Reduce Product Adoption.
January 2023 - Cipla Inc. launched a point-of-care testing device, Cippoint. The device is CE IVD-approved and helps diagnose non-communicable and infectious diseases.
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4850, USD 5850, and USD 6850 respectively.
The market size is provided in terms of value, measured in USD Billion and volume, measured in K Units.
Yes, the market keyword associated with the report is "Infectious Disease Point-of-care (POC) Diagnostics Market," which aids in identifying and referencing the specific market segment covered.
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
To stay informed about further developments, trends, and reports in the Infectious Disease Point-of-care (POC) Diagnostics Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.